Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

about

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

P2860

Q41622226-BA2B8EE7-ACBF-41EB-9A6B-4074D7898563

P2860

Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

Item

http://www.wikidata.org/entity/Q50529551

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Relationship between response ...... of published clinical trials.

@en

Relationship between response ...... of published clinical trials.

@nl

type

Item

label

Relationship between response ...... of published clinical trials.

@en

Relationship between response ...... of published clinical trials.

@nl

prefLabel

Relationship between response ...... of published clinical trials.

@en

Relationship between response ...... of published clinical trials.

@nl

P1476

Relationship between response ...... of published clinical trials.

@en

P2093

Ahmed Hamed Salem

http://www.w3.org/2001/XMLSchema#string

Kevin J Freise

http://www.w3.org/2001/XMLSchema#string

Mengyao Li

http://www.w3.org/2001/XMLSchema#string

Naveen Mangal

http://www.w3.org/2001/XMLSchema#string

Rajeev Menon

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.

Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.

Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

P304

37-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/HON.2463

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28707346

http://www.w3.org/2001/XMLSchema#string

Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

about

P2860

P2860

Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698